THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at ... read more

THOUSAND OAKS, Calif., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from ... read more

THOUSAND OAKS, Calif., Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a conference call with ... read more

THOUSAND OAKS, Calif., Jan. 4, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at the Westin St. Francis in San Francisco, Calif. Robert A. Bradway, president and ... read more

THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application ... read more

THOUSAND OAKS, Calif. and PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and ... read more

THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Kevin W. Sharer, chairman and chief executive officer of Amgen (NASDAQ:AMGN) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen. To facilitate an ... read more

THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the first quarter of 2012. This represents an approximate 29 percent increase from that paid in the previous two quarters. The dividend ... read more

THOUSAND OAKS, Calif., Dec. 14, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011. Amgen has accepted for purchase 83,333,333 shares ... read more

THOUSAND OAKS, Calif., Dec. 8, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011. Based on the preliminary count by American ... read more

THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patients and institutions are no longer required to enroll in ... read more

THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer (CRPC). Published in ... read more

THOUSAND OAKS, Calif., Nov. 14, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen will be meeting with investors in Europe this week with a view to raise $1-1.5 billion in Euro and Sterling denominated debt to support its share repurchase program, as well as for general corporate purposes. ... read more

THOUSAND OAKS, Calif., Nov. 7, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par value $0.0001 per share ("Common Stock"). Amgen also announced a public offering of its senior ... read more

THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease ... read more

THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal women with osteoporosis was associated with continued increase ... read more

THOUSAND OAKS, Calif., Oct. 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the third quarter of 2011 to $3,944 million versus $3,816 million in the third quarter of 2010. Total product sales increased 3 percent in the third quarter of 2011 to $3,877 ... read more

THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Monday, Oct. 24, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 ... read more

THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the Company's ... read more

THOUSAND OAKS, Calif., Oct. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that its Board of Directors has appointed Robert A. Bradway to the Company's Board. Bradway, 48, is Amgen's president and chief operating officer. The addition of Bradway brings the number of Amgen board members to ... read more